The Arcturus Therapeutics Holdings (NASDAQ:ARCT) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT). Its share price is already up an impressive 114% in the last twelve months. Better yet, the share price has risen 7.7% in the last week. We'll need to follow Arcturus Therapeutics Holdings for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.
See our latest analysis for Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
Over the last twelve months, Arcturus Therapeutics Holdings's revenue grew by 149%. That's stonking growth even when compared to other loss-making stocks. Meanwhile, the market has paid attention, sending the share price soaring 114% in response. It's great to see strong revenue growth, but the question is whether it can be sustained. Given the positive sentiment around the stock we're cautious, but there's no doubt its worth watching.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So it makes a lot of sense to check out what analysts think Arcturus Therapeutics Holdings will earn in the future (free profit forecasts).
A Different Perspective
Arcturus Therapeutics Holdings boasts a total shareholder return of 114% for the last year. We regret to report that the share price is down 0.3% over ninety days. Shorter term share price moves often don't signify much about the business itself. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.
Arcturus Therapeutics Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
